Pfizer Inc. Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the successful completion of the initial cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.

Back to news